Figure 7From: Molecular pathogenetic mechanisms and new therapeutic perspectives in anthracycline-induced cardiomyopathyPotential therapeutic use of B1 and B2 kinin receptors (B1R, B2R) modulators to prevent anthracycline-induced myocardial damage.Back to article page